Clinical trials: Hematological Patients
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01399840
- Testing
- BMN 673
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
Anemia
The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia
This will be a randomised control trial designed to test the effectiveness of lactoferrin in the management of treatment-induced anemia in patients with hematological malignancies.
- Trial name
- NCT03683810
- Testing
- Lactoferrin, Recombinant human erythropoietin
- Where
- 2 sites in Cyprus
- Volunteers
- 50 people
- Sponsor
- Cyprus University of Technology
Hematological Patients, Newly Diagnosed Multiple Myeloma
Biomarkers in Multiple Myeloma
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in…
- Conditions
- Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy
- Trial name
- VESICOM (NCT05259553)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Diabetes Type 2, Hematologic Malignancy
Effect of Smartphone App on Activity
A smartphone app will be installed on smartphones of patients with type 2 diabetes or hematologic malignancies that do not exercise. The app will send SMS messages to encourage exercise.
- Trial name
- NCT02612402
- Testing
- messages generated by learning algorithm, constant weekly message reminding patient to exercise
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- Rambam Health Care Campus
Acute Graft Versus Host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).
- Trial name
- NCT07047456
- Testing
- Time of umbilical cord blood infusion
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Anhui Provincial Hospital
Hematologic Malignancy
T-cell Developmental Status in Patients With Malignant Hematological Tumors
To evaluate the immune status and prognosis of patients with malignant hematological tumors, thereby guiding clinical therapeutic strategies.
- Trial name
- NCT07035938
- Testing
- observational study
- Where
- China
- Volunteers
- 75 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
COVID19, Hematologic Malignancy
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among…
- Trial name
- HYACINTHE (NCT04392128)
- Testing
- Hydroxychloroquine Sulfate 200 MG [Plaquenil], Azithromycin 250 MG Oral Capsule
- Where
- France
- Sponsor
- Institut de cancérologie Strasbourg Europe
Secondary Antibody Deficiency
Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
Current treatment for patients with secondary antibody deficiency (SAD) is Immunoglobulin replacement therapy (IGRT). There are currently no clinical guidelines for IGRT discontinuation in patients with SAD.
- Trial name
- SAD (NCT05612607)
- Testing
- Immunoglobulin replacement therapy (IGRT)
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
- Trial name
- HAPLOTAB (NCT05236764)
- Testing
- CliniMACS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Hematological Neoplasm, Endothelial Dysfunction
The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms
The endothelium is a semipermeable monolayer of endothelial cells (EC) organized as a complex biological interface that separates all tissues from circulating blood.
- Trial name
- EndoCDO-H (NCT05502887)
- Testing
- Sublingual in vivo microscopy with the Glycocheck microscope
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Prof. Dr. Thomas Luft
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma
- Trial name
- NCT01221857
- Testing
- NiCord®
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gamida Cell ltd
Hematological Malignancies
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the…
- Trial name
- NCT01607892
- Testing
- KPT-330
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Karyopharm Therapeutics Inc
Hematological Malignancy, Solid Tumor
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors.
- Trial name
- NCT05828459
- Testing
- OT-A201, IMids, Bevacizumab
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Onward Therapeutics
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.
- Trial name
- NCT00472368
- Testing
- LBH589
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL)
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
This was a Phase 2, international, multicenter, open-label, single-arm trial evaluating Marqibo (VSLI) in adult subjects with: 1) Ph- ALL or lymphoblastic lymphoma in second or greater relapse; or 2) Ph- ALL or lymphoblastic…
- Trial name
- NCT00495079
- Testing
- Marqibo® (vincristine sulfate liposomes injection)
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Cancer Survivors
Cancer Survivorship in Hematologic Malignancies
General objective: to improve care for haematological cancer survivors. This study will (i) Estimate the incidence of cancer survivor syndrome (CSS) in adult Egyptian patients with haematological neoplasms (HN).
- Trial name
- NCT05780411
- Testing
- questionnaire
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Cancer, Leukemia
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
In this study two cord blood collections will be used to increase the number of cord blood cells you will receive on transplant day. We call this a "double unit" cord blood transplant.
- Conditions
- Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT00597519
- Testing
- Fludarabine, Cyclophosphamide, Transplantation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematologic Diseases, Stem Cell Transplant Complications
ALLO-SCT in Elderly Patients With Hematological Disease
Retrospective, observational, multicentre, spontaneous, non-interventional study This study will evaluate all consecutive patients older than 60 years who received hematopoietic stem cell transplantation (HSCT) between 1st…
- Trial name
- NCT04386928
- Where
- 29 sites in Italy
- Volunteers
- 1,996 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hematological Malignancy
Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers
This study will address whether teaching the Body Scan exercise to cancer patients with hematological malignancies and their caregivers during an inpatient hospitalization improves reported physical and psychological symptoms…
- Trial name
- NCT03611764
- Testing
- Body Scan, Rotterdam Symptom Checklist, Practice Logs
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine